Invivoscribe® is a comprehensive CDx partner, providing ISO 13485 compliant biomarker development, cGMP manufacturing, regulatory capability, clinical trial services, and global commercialization. It offers internationally standardized testing through ISO 15189 laboratory network (US, Europe, Asia). Its Streamlined CDx™ model has proven successful in accelerating FDA, EMA and PMDA approvals of new targeted therapies.
Myriad RBM, Inc. is a CLIA certified, multiplexed immunoassay testing laboratory that solves complex drug development challenges with innovative biomarker services. Myriad RBM’s internally developed and manufactured immunoassay kits based on Multi-Analyte Profiling (MAP) and ultrasensitive Single-Molecule Array (SimoaTM) technology, provide reproducible and quantitative data for hundreds of human proteins.
Imagia brings together healthcare expertise and advanced artificial intelligence to diagnose, treat, and cure high burden diseases. Through its EVIDENS platform, Imagia enables its stakeholders to learn from distributed healthcare data and discover AI-driven clinical solutions. Working collaboratively with hospital, biotech, pharma, and medical device partners, Imagia is on a mission to unleash the potential of all data across all organizations to achieve medical breakthroughs.
Paragon Genomics, Inc. specializes in sample preparation for targeted next-generation sequencing (NGS). We develop and commercialize reagents and molecular diagnostic tools for genomic analysis of clinically-relevant samples. Our CleanPlex® and CleanPlex® UMI NGS panels combine superior primer design and innovative library preparation chemistry to eliminate non-specific PCR products, incorporate molecular identifiers, and achieve superior target enrichment and variant detection performance.